Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.